カレントテラピー　35-8　サンプル page 28/34

このページは カレントテラピー　35-8　サンプル の電子ブックに掲載されている28ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　35-8　サンプル

Current Therapy 2017 Vol.35 No.8 81治療薬解説79512）Yano S, Shinohara H, Herbst RS, et al：Production of experimentalmalignant pleural effusions is dependent on invasionof the pleura and expression of vascular endothelial growthfactor/vascular permeability factor by human lung cancercells. Am J Pathol 157：1893-1903, 200013）Yano S, Herbst RS, Shinohara H, et al：Treatment for malignantpleural effusion of human lung adenocarcinoma by inhibitionof vascular endothelial growth factor receptor tyrosinekinase phosphorylation. Clin Cancer Res 6：957-965, 200014）Kitamura K, Kubota K, Ando M, et al：Bevacizumab pluschemotherapy for advanced non-squamous non-small-celllung cancer with malignant pleural effusion. CancerChemother Pharmacol 71：457-461, 201315）Usui K, Sugawara S, Nishitsuji M, et al；North East JapanStudy Group：A phase Ⅱstudy of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinomapatients with malignant pleural effusions：North EastJapan Study Group Trial NEJ013A. Lung Cancer 99：131-136, 201616）Socinski MA, Langer CJ, Huang JE, et al：Safety of bevacizumabin patients with non-small-cell lung cancer and brainmetastases. J Clin Oncol 27：5255-5261, 200917）Besse B, Le Moulec S, Mazieres J, et al：Bevacizumab inPatients with Nonsquamous Non-Small Cell Lung Cancerand Asymptomatic, Untreated Brain Metastases（BRAIN）：A Nonrandomized, PhaseⅡStudy. Clin Cancer Res 21：1896-1903, 201518）Barlesi F, Gervais R, Lena H, et al：Pemetrexed and cisplatinas first-line chemotherapy for advanced non-small-cell lungcancer（NSCLC）with asymptomatic inoperable brain metastases：a multicenter phaseⅡtrial（GFPC 07-01）. Ann Oncol22：2466-2470, 201119）Seto T, Kato T, Nishio M, et al：Erlotinib alone or with bevacizumabas first-line therapy in patients with advanced nonsquamousnon -small -cell lung cancer harbouring EGFRmutations（JO25567）：an open-label, randomised, multicentre,phase 2 study. Lancet Oncol 15：1236-1244, 201420）Garon EB, Ciuleanu TE, Arrieta O, et al：Ramucirumab plusdocetaxel versus placebo plus docetaxel for second -linetreatment of stageⅣnon-small-cell lung cancer after diseaseprogression on platinum-based therapy（REVEL）：amulticentre, double-blind, randomised phase 3 trial. Lancet384：665-673, 201421）Yoh K, Hosomi Y, Kasahara K, et al：A randomized, doubleblind,phase Ⅱ study of ramucirumab plus docetaxel vs placeboplus docetaxel in Japanese patients with stageⅣnon -small cell lung cancer after disease progression on platinumbasedtherapy. Lung Cancer 99：186-193, 2016